Intrathecal Therapy For Severe Chronic Pain Therapeutics
1. Prialt patent expiration
Treatment: Treatment of pain; Analgesia; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5795864 | TERSERA | Stable omega conopetide formulations |
Jun, 2015
(10 years ago) | |
| US5364842 | TERSERA | Method of producing analgesia |
Dec, 2016
(9 years ago) | |
| US8653033 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(1 year, 3 months ago) | |
| US9707270 | TERSERA | Method for administering ω-conopeptide |
Oct, 2024
(1 year, 3 months ago) | |
| US8765680 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(1 year, 3 months ago) | |
Drugs and Companies using ZICONOTIDE ACETATE ingredient
Market Authorisation Date: 28 December, 2004
Dosage: INJECTABLE
More Information on Dosage
PRIALT family patents
